Research Paper Volume 15, Issue 24 pp 15640—15656
Protective effect of fluoxetine against oxidative stress induced by renal ischemia-reperfusion injury via the regulation of miR-450b-5p/Nrf2 axis
Figure 6. Fluoxetine pre-treatment relieved oxidative stress via miR-450b-5p/Nrf2 axis in renal IRI rats. (A) H&E staining of renal tissues in IRI group and IRI+FLX group at 3 and 21 days after operation after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2 in male rats (magnification ×400). (B) Masson staining was used to evaluate renal injury and fibrosis in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. (C) DHE staining of renal tissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. ROS exhibit red fluorescence under fluorescent microscope (magnification ×400). (D) Immunohistochemical analysis showed the expression level of iNOS from renal tissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2 in male rats (magnification ×400). (E) Content of MDA of renal ischemia tissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. (F) Content of 8-OHdG of renal ischemia tissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. (G) Content of T-AOC of renal ischemiatissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. (H) Content of GSH of renal ischemia tissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. (I) Western Blotting analysis showed the expression level of NF-κB, Nrf2 and Nrf2-dependent antioxidant enzymes, including HO-1, NQO1 and GST from renal tissues in IRI group and IRI+FLX group after the injection of miR-450b-5p agomir or miR-450b-5p agomir+Recombinant protein Nrf2. Data were presented as Mean ± SD, *significant difference (P < 0.05).